Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Posted: February 21, 2024 at 2:34 am
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Follow this link:
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Posted in Global News Feed
Comments Off on PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Arvinas Announces Chief Financial Officer Transition
Posted: February 21, 2024 at 2:34 am
- Sean Cassidy leaving Arvinas as of February 29, 2024 -
Read more:
Arvinas Announces Chief Financial Officer Transition
Posted in Global News Feed
Comments Off on Arvinas Announces Chief Financial Officer Transition
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Posted: February 21, 2024 at 2:34 am
BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on February 16, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read the original post:
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Posted in Global News Feed
Comments Off on Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
Posted: February 21, 2024 at 2:34 am
Montrouge, France, February 20 2024
Read more:
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
Posted in Global News Feed
Comments Off on DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
Posted: February 21, 2024 at 2:34 am
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.
Follow this link:
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
Posted in Global News Feed
Comments Off on Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
Posted: February 21, 2024 at 2:34 am
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced with sadness that P. Joseph Campisi, Jr., Esq, the Company’s Chief Legal Officer, passed away on February 1, 2024, following a prolonged battle with cancer.
Read the original here:
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
Posted in Global News Feed
Comments Off on Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
Posted: February 21, 2024 at 2:34 am
IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
See the rest here:
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
Posted in Global News Feed
Comments Off on Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
Sanofi: Information concerning the total number of voting rights and shares – January 2024
Posted: February 21, 2024 at 2:34 am
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
Read more from the original source:
Sanofi: Information concerning the total number of voting rights and shares - January 2024
Posted in Global News Feed
Comments Off on Sanofi: Information concerning the total number of voting rights and shares – January 2024
PolTREG appoints Dan Shelly as Chief Business Development Officer
Posted: February 21, 2024 at 2:34 am
Posted in Global News Feed
Comments Off on PolTREG appoints Dan Shelly as Chief Business Development Officer
Bavarian Nordic delivered record financial results in 2023
Posted: February 21, 2024 at 2:34 am
COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provides an update on its R&D priorities.
See the rest here:
Bavarian Nordic delivered record financial results in 2023
Posted in Global News Feed
Comments Off on Bavarian Nordic delivered record financial results in 2023
